CPC A61K 47/6923 (2017.08) [A61K 31/573 (2013.01); A61K 47/52 (2017.08); A61K 47/6929 (2017.08); A61P 29/00 (2018.01)] | 8 Claims |
1. A method of reducing inflammation in a patient, comprising administering a composition comprising octadecylamine surface-functionalized nanodiamonds, wherein the surface functionalized nanodiamonds do not bind a substantial amount of a therapeutic agent, wherein the surface-functionalized nanodiamonds have a particle size of between about 1 to about 10 μm in diameter.
|